At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Non Small Cell Lung Cancer. Completed, enrolled 83 participants across 12 sites.
Detailed Summary
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1). 82 patients will be enrolled in this trial to examine the efficacy, the impact on geriatric assessments, the quality of life and the self-reported outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedSep 2017
Primary CompletionApr 2023
Study CompletionJul 2023
TodayJul 2026
First PostedSep 26, 2017
Enrollment StartJan 15, 2017
Primary CompletionApr 28, 2023
Study CompletionJul 15, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 8.8 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab (MK-3475) 200 mg, every 3 weeks